Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital
09 févr. 2015 08h00 HE
|
Melinta Therapeutics
New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a
$30 million growth capital debt financing agreement with Hercules
Technology Growth...
Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil
08 janv. 2015 15h08 HE
|
Melinta Therapeutics
NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the
largest pharmaceutical companies in Brazil, announced that...
Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI
07 janv. 2015 13h40 HE
|
Melinta Therapeutics
New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced positive top-line results from the first of two
Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...
Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae
08 sept. 2014 11h01 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results from in vitro studies that highlight the
potential of delafloxacin, an
investigational fluoroquinolone,...
Melinta Therapeutics Reports on PK Profile of a Single Oral Dose of Delafloxacin in Support of U.S. Phase 3 Gonorrhea Program
06 sept. 2014 12h01 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results of a Phase 1 study of delafloxacin, an
investigational fluoroquinolone, in healthy adults that...
Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting
04 sept. 2014 10h45 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that an additional three abstracts have been accepted as
late-breakers at the annual Interscience Conference...
Melinta Therapeutics Bolsters Board of Directors with Appointment of Christopher Kiritsy
14 août 2014 10h38 HE
|
Scienta Communications
NEW HAVEN, Conn, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Christopher Kiritsy to the Company's
Board of Directors. Mr. Kiritsy is currently president,...
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
11 août 2014 12h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced top-line results of a Phase 1 clinical study that
demonstrated that the administration of single doses of...
Melinta Therapeutics Announces Accepted Abstracts at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
24 juil. 2014 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, July 24, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that the company and investigators will be making eight
presentations at the annual Interscience Conference...
Melinta Therapeutics to Present at Annual JMP Securities Healthcare Conference
17 juin 2014 14h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, June 17, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that CEO Mary Szela will be presenting at the annual JMP
Securities Healthcare Conference in New York, NY....